AstraZeneca Plc (STO: AZN) reported on Tuesday that as of 31 December 2017, the issued share capital of the company with voting rights was 1,266,221,605 ordinary shares of USD0.25.
Also, no shares are held in treasury. Therefore, the total number of voting rights in AstraZeneca Plc was 1,266,221,605.
According to the company this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca Plc under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca is a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular & Metabolic Diseases and Respiratory. It is also selectively active in the areas of autoimmunity, neuroscience and infection.
GSK wins European Commission approval for Shingrix prefilled syringe
Tri-City Cardiology adds new members to care team
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
InsiteOne agrees strategic partnerships with ASCEND Cardiovascular and Apollo Enterprise Imaging
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures